- Home
- COYA vs GNLX Comparison
COYA vs GNLX Comparison
Compare COYA & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$4.00
HOLD
Current Price
$2.57
Company Overview
Basic Information| Metric | COYA | GNLX |
|---|---|---|
| Founded | 2020 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.6M | 113.6M |
| IPO Year | 2022 | 2022 |
Fundamental Metrics
Financial Performance| Metric | COYA | GNLX |
|---|---|---|
| Price | $4.00 | $2.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $15.80 | ★ $19.80 |
| AVG Volume (30 Days) | 120.6K | ★ 150.5K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,945,753.00 | $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,050.79 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 123.57 | N/A |
| 52 Week Low | $3.71 | $1.99 |
| 52 Week High | $7.75 | $8.54 |
Technical Indicators
Market Signals| Indicator | COYA | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 37.61 | 48.69 |
| Support Level | $3.94 | $2.54 |
| Resistance Level | $5.16 | $3.00 |
| Average True Range (ATR) | 0.25 | 0.16 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 30.92 | 56.00 |
Price Performance
Historical Comparison COYA
GNLX
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.